Sanofi (NASDAQ:SNY) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a research report report published on Sunday morning.

Several other equities analysts have also recently issued reports on SNY. Morgan Stanley set a $49.00 target price on shares of Sanofi in a research note on Wednesday, July 8th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a research note on Monday, April 20th. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Weiss Ratings downgraded shares of Sanofi from a “hold (c-)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, Argus upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $49.50.

Sanofi Price Performance

SNY stock opened at $43.46 on Friday. Sanofi has a 1-year low of $40.89 and a 1-year high of $52.68. The business has a fifty day moving average price of $43.31 and a 200-day moving average price of $45.04. The company has a debt-to-equity ratio of 0.21, a current ratio of 0.99 and a quick ratio of 0.64. The stock has a market capitalization of $105.37 billion, a P/E ratio of 22.75, a P/E/G ratio of 1.08 and a beta of 0.35.

Institutional Trading of Sanofi

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Flagship Harbor Advisors LLC purchased a new position in shares of Sanofi during the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. increased its stake in Sanofi by 180.5% in the 1st quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after buying an additional 379 shares in the last quarter. Western Wealth Management LLC purchased a new stake in Sanofi in the 1st quarter worth $29,000. Leonteq Securities AG raised its holdings in Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after acquiring an additional 297 shares during the period. Finally, Measured Wealth Private Client Group LLC bought a new stake in Sanofi during the third quarter valued at about $29,000. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.